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Abstract  
Objective: The study was carried out to assessment or to evaluate chloroquine Resistance of Plasmodium falciparum among 
Sudanese populations (10–85 years) ,malaria endemic area in Sennar region (Sennar state in South East Sudan) and 
Khartoum State (the capital). 
Design: The study was carried out on 190 samples of all of the study areas between March and December 2007, 
corresponding to the period of high malaria transmission. All samples were tested for chloroquine  Resistance to  
Plasmodium falciparum by using in vitro micro tests.  These study sites are located in an irrigated agricultural scheme, 
where transmission is seasonal. 
Setting: AL-Neelain University – College of Medical Laboratory Sciences – Sudan – Khartoum. 
Results: By using in vitro micro tests: In Sennar state the resistance to chloroquine was found to be 78.1% and about 21.9% 
were sensitive. Out of 105 patients only 23 patients(21.9%) were sensitive and 82 patients(78.1%) did not respond, 29 
patients(27.6%), 19 patients (18.1%) and 34 patients (32.4%) of  a total of 105 patients were early R1, RII and RIII  levels 
of  resistance respectively. In Khartoum state the the resistance to chloroquine was found to be 68.2% and about 31.8% 
were sensitive. Out of 85 patients only 27 patients (31.8%) were sensitive and 58 patients (68.2%) did not respond, 35 
patients (41.2%) and 23 patients (27.1%) of a total of 85 patients were early R1 and RII levels of resistance respectively. 
Conclusions: By using in vitro micro tests: In Sennar state the resistance to chloroquine was found to be 78.1% and about 
21.9% were sensitive while in Khartoum state the the resistance to chloroquine was found to be 68.2% and about 31.8% 
were sensitive. 
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INTRODUCTION 
 
     Malaria is a complex disease that varies widely in epidemiolog 
and clinical manifestation in different parts of the world. This 
variability is the result of factors such as the species of malaria 
parasites that occur in a given area, their susceptibility to commonly 
used or available antimalarial drugs, the distribution and efficiency of 
mosquito vectors, climate and other environmental conditions and 
the behaviour and  level of acquired immunity of the exposed 
human populations. 
     Drug resistance has also played a significant role in the 
occurrence and severity of epidemics in some parts of the world. 
Population movement has introduced resistant parasites to areas 
previously free of drug resistance. The economics of developing new 
pharmaceuticals for tropical diseases, including malaria, are such 
that there is a great disparity between the public health importance of 
the disease and the amount of resources invested in developing new 
cures.(1,2) Chloroquine was discovered in 1934 by Hans Andersag 
and co-workers at the Bayer laboratories who named it "Resochin". It 
was ignored for a decade because it was considered too toxic for 
human use. During World War II, United States government- 
ponsored clinical trials for anti-malarial drug development showed 
unequivocally that chloroquine has a significant therapeutic value as 
an anti-malarial drug. It was introduced into clinical practice in 1947 
for the prophylactic treatment of malaria.[3] 
     It has long been used in the treatment or prevention of 
malaria. After the malaria parasite Plasmodium falciparum started to 
develop widespread resistance to chloroquine,[4][5] new potential 
utilisations of this cheap and widely available drug have been 
investigated. Chloroquine has been extensively used in mass drug 
administrations which may have contributed to the emergence and 
spread of resistance.( 5) 
     Plasmodium falciparum which is resistant to chloroquine—a 
pharmacologic ‘staple’ used to treat and as prophylaxis for visitors to 
malaria endemic regions of Africa Mechanism of resistance 
Resistant strains of P falciparum do not concentrate chloroquine; 
resistance is reversed by verapamil, a calcium channel blocker.(6) 
     Sudan is the largest country in Africa, covering over 8% of the 
entire continent. The total population is estimated to be 30.3 million 
inhabitants, of which 75% live in rural areas. There are 7.5 million 
malaria cases and 35 000 deaths every year due to malaria. The 
problem appears to have worsened in recent years, due to 
increasing levels of P. falciparum resistance against the two most 
commonly used antimalarials: CQ and Fansidar.( 7)  
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     Malaria is a major health problem in about 100 countries. 
More than 40% of the world population live in malaria endemic areas, 
and almost half of them in Sub-Saharan Africa where about 90% of 
the clinical cases occur. There are nearly 500 million clinical cases of 
malaria worldwide each year and 1.1 to 2.7 millions die annually, the 
majority of whom are children under  5 years in Africa.(8, 9) 
     Chloroquine is a 4-aminoquinoline derivative of quinine, first 
synthesized in 1934 and has since been the most widely used 
antimalarial and the treatment of choice for uncomplicated malaria 
and for prophylaxis as well. Chloroquine resistant P.falciparum 
malaria has been reported in all areas where the parasite is 
transmitted except for malarious areas of Central America, the island 
of Hispaniola, and limited areas of the Middle East and Central Asia. 
As the malaria parasite digests haemoglobin, large amounts of a 
toxic by-product are formed. The parasite polymerizes this by-
product in its food vacuole, producing a non-toxic haemozoin 
(malaria pigment). It is believed that resistance of P. falciparum to 
chloroquine is related to an increased capacity for parasite to expel 
chloroquine at a rate that does not allow chloroquine to reach levels 
required for inhibition of haem polymerization.(10) 
     This chloroquine efflux occurs at a rate of 40 to 50 times 
faster among resistant parasites  than sensitive ones (11). Further 
evidence supporting this mechanism is provided by the fact that 
chloroquine resistance can be reversed by drugs which interfere with 
this efflux system(12). It is unclear whether parasite resistance to 
other quinolone antimalarials (amodiaquine, mefloquine, halofantrine, 
and quinine) occurs via similar mechanisms (10).  
     Sudan is the largest country in Africa, comprising more than 
8% of the entire continent. The total population is estimated to be 
39.2 million inhabitants, of whom 75% live in rural areas. Malaria is a 
leading cause of morbidity and mortality, resulting in 3.1 million 
cases and 2,500 deaths annually(13). 
 
MATERIALS AND METHODS 
 
     This study was carried out on 190 samples (two study area) of  
patients infected by plasmodium malaria by collected from Khartoum 
state and Sennar region. The samples was tested for chloroquine 
resistance of plasmodium falciparum by using in vitro micro tests. 
removing the parasites from the host and placing them into a 
controlled experimental environment. In the microtechnique most 
frequently used, parasites obtained from venous blood sample and 
finger-prick blood sample are exposed in microstate plates to 
precisely known quantities of drug and observed for inhibition of 
maturation into schizonts.(14) 
 
In vitro test 
 
     The micro-technique test (Mark III: supplied by WHO Division 
of Control of Tropical Disease 2001, England) was used to evaluate 
in vitro sensitivity to CQ of P. falciparum malaria parasites. One 
hundred and ninety malaria cases were selected for this study, 
according to the in vitro protocol described in Mark III-WHO(15). The 
test was performed in tissue culture plates pre-dosed with drugs in 
increasing concentrations; briefly, 0.9 mL of RPMI 1640 medium 
were taken into the sterile falcon tube and 100 µL from well-mixed 
blood mentioned previously were added. All wells of appropriate 
columns were dosed with 50 µL of blood-medium mixture using the 
50 µL fixed volume Eppendorf pipette and a disposable sterile tip, as 
provided with the test kit. Plates were incubated at 37.5°C in a 
candle jar for 24 to 30 h. At the end of incubation, blood from each 
well was harvested and a thick film was prepared; thick films were 
stained for 30 min in a Giemsa stain at a dilution of 1% (vol/vol) in 
buffered water of pH 6.8. After drying, films were examined through a 
light microscope with oil immersion lens, and the number of 
schizonts with three or more nuclei of a total of 200 asexual 
parasites (i.e., schizonts and trophozoites) was counted. For an 
acceptable test, schizont maturation in control must be 10% or more 
(i.e., 20 schizonts with three or more nuclei per 200 asexual 
parasites). Average results for EC50, EC90, EC95, and EC99 (i.e., 
drug concentrations producing 50%, 90%, 95%, or 99% inhibition of 
schizont maturation, respectively) were calculated using the WHO 
log probit program (www.who.int/csr/drugresist/malaria/en/probit.xls) 
in all isolates.     
 
RESULTS 
 
     By using in vitro micro tests: In Sennar state the the 
resistance to chloroquine was found to be 78.1% and about  21.9% 
were sensitive. Out of 105 patients only 23 patients(21.9%) were 
sensitive and 82 patients(78.1%) did not respond, 29 
patients(27.6%), 19 patients (18.1%) and 34 patients (32.4%) of  a 
total of 105 patients were early R1, RII and RIII  levels of  
resistance respectively.  
     In Khartoum state the the resistance to chloroquine was found 
to be 68.2% and about 31.8% were sensitive. Out of 85 patients only 
27 patients(31.8%) were sensitive and 58 patients(68.2%) did not 
respond, 35 patients(41.2%) and  23 patients (27.1%) of  a total of  
85 patients were early R1 and RII levels of resistance respectively. 
 
Table 1.Chloroquine resistance to plasmodium falciparum in Sennar state: 
 
Level of resistance 
 
Patients 
RI RII RIII 
Total number of patients 105 105 105 
Number of not respond patients 29 19 34 
Percent of not respond patients 27.6% 18.1% 32.4% 
 
 
Chloroquine resistance to plasmodium falciparum in Sennar state 
 
 
Table 2. Chloroquine resistance to plasmodium falciparum in Khartoum state 
 
level of resistance 
 
Patients 
RI RII RIII 
Total number of patients 85 85 85 
Number of not respond patients 35 23 -- 
Percent of not respond patients 41.2% 27.1% -- 
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Chloroquine resistance to plasmodium falciparum in Khartoum state 
 
DISCUSSION AND CONCLUSIONS 
 
     Antimalarial drug resistance is widely monitored using in-vitro 
susceptibility testing. There are sentinel sites throughout the malaria 
affected world monitoring for drug resistance. A variety of methods 
have been developed and the results have provided valuable 
information in the assessment and mapping of antimalarial drug 
resistance (16).Evaluation of stored isolates in reference centres 
allows proper standardisation of methodologies and repeated tests 
on single isolates. But most of this testing in the field is a "one-off" 
microtest on freshly obtained blood samples. When antimalarial drug 
susceptibility tests are reported the highest observed values 
observed are naturally of greatest interest as they may represent 
emerging drug resistance. Drug regimens should aim to cure all 
infections, and thus provide concentrations exceeding the inhibitory 
concentrations for the most resistant prevalent parasites. If only a 
single concentration range is evaluated in an in-vitro susceptibility 
assay using serial dilutions then, by definition, the true EC50 of the 
most resistant isolates must lie above or between the largest 
concentration differences tested. Thus, unless the parasites are 
retested with a higher concentration range (which they usually 
cannot be), the precision of the estimated EC50 or EC90 value of the 
most resistant isolate will usually be the poorest of all the isolates 
assayed. Furthermore as curve fitting or probit analysis takes no 
account of other isolates in the series tested, then if there are two 
adjacent points with extremely different values (often zero and 100% 
inhibition), a curve will be fitted as lying symmetrically between the 
two. 
     Antimalarial drugs will continue to be needed in the future 
despite the progress in malaria research at all fronts relevant to the 
parasite, the vector and the human host, in particular the areas of 
vector control, epidemiology, molecular biology, immunology and 
therapeutics. As long as drugs are used, chances of developing 
resistance are there, especially for P. falciparum the most serious 
and widely spread strain of human malaria parasites. Currently, the 
development of resistance is more rapid than the pace in the 
discovery of new effective and affordable drugs. Thus, the challenge 
is how to make maximum use of available drugs and to prolong the 
useful lifespan with the hope that new drugs or other methods of 
control will be developed and implemented. Firstly, there is need to 
improve prescription procedures and stop over-counter purchase of 
antimalarials. 
     In addition, there is need to upgrade focused malaria training 
and to raise awareness on the magnitude of the problem at all levels 
of health personnel. Improved access to and use of definitive 
diagnosis-based treatment is essential. 
     Furthermore, prevention of drug resistance can be attained by 
reducing drug pressure through more selective use of drugs 
particularly combination therapy which is inherently less likely to 
foster resistance or have properties that do not facilitate 
development or spread of resistance. There is need to identify 
strategies to improve acceptance of and compliance with 
combination therapy at all levels-official and non-official healthcare 
systems, private sector, and community.(17) 
     Because of the realities of health care infrastructure and the 
influence of the private sector, approaches to malaria therapy, 
especially in sub-Saharan Africa, will probably favour increased 
access to drugs (and, therefore, loss of control over how they are 
used) over restricted access (and, therefore, more control over how 
they are used).  
     If this proves to be true, while only minor advances against 
antimalarial drug resistance can be expected, short-term reductions 
in malaria morbidity and mortality may be achieved. 
     Long-term success of this strategy, however, will depend on a 
continuous supply of new and affordable drugs and on the 
development of effective and implementable control measures to 
reduce overall burden of disease. A more cautious approach would 
be to avoid placing too much faith in future scientific advances and 
technology and to invest in methods to improve the way people and 
antimalarial drugs interact in an environment of essentially 
uncontrolled use. The objective of this investment would be to 
prolong the useful life span of drugs enough to increase the 
likelihood that new drugs or other methods of malaria control will 
indeed be developed and implemented. 
     Significant advances against antimalarial drug resistance is 
probably unlikely without major change in health infrastructure 
leading to higherquality services that are more readily available.(18) 
     A strategy that has received much attention recently is the 
combination of antimalarial drugs, such as mefloquine,  
sulfadoxine/ pyrimethamine (SP), or amodiaquine, with an 
artemisinin derivative. (19) 
     Another approach that has not been widely adopted is the 
close follow-up and re-treatment, if necessary, of patients. The 
success of this approach is dependant on availability of reliable 
microscopy (to diagnose the illness initially as well as to confirm 
treatment failure), and either an infrastructure to locate patients in 
the community or a community willing to return on a given date, 
regardless of whether they feel ill or not. With this system, patients 
who fail initial treatment, for whatever reason, are identified quickly 
and re-treated until parasitologically cured, decreasing the potential 
for spread of resistant parasites.(20) 
 
PRIORITIES 
A. Investigate combination therapy 
1. Fast-track a chlorproguanil/dapsone/ artesunate fixed dose 
formulation. From a theoretical basis, this would offer the best 
combination of overall efficacy, synergy between the 
antifolate-sulfa components, short half-life, reasonably well-
matched pharmacokinetics, and probable cost. Because of 
growing use of and resistance to SP, an urgency exists to 
field this promising agent. 
2. Investigate effectiveness of combination therapy in terms of 
robustness of strategy in face of high levels of self-treatment 
and unofficial use of component drugs (or related 
compounds) as monotherapy and in various epidemiological 
contexts (especially hightransmission areas). 
3. Investigate how a combination therapy strategy could be 
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financed. This strategy, if proven cost-effective, will 
nonetheless be more expensive than current strategies. What 
mechanisms might be developed to assist countries in 
adopting this strategy? 
B. Invest significantly in identifying strategies to improve 
acceptance of and compliance with drug regimens, especially 
a combination therapy strategy, at all levels of official and 
unofficial health care systems, private sector, and community. 
Similarly, investigate to teach concepts of judicious use of 
antimicrobials (including antimalarial drugs) to health care 
providers. 
C. Investigate ways to improve effectiveness of drug regulatory 
systems and ability to control introduction of new antimalarials 
within endemic countries. This is required to avoid uncontrolled 
use of new antimalarials resulting in development of resistance 
before they are needed which could significantly compromise 
their efficacy when they are needed. 
D. Support new drug development. Investigate new approaches to 
drug delivery, such as timereleased formulations or novel 
delivery systems that would allow use of short half-life drugs 
while optimizing compliance. Investigate drugs (or vaccines?) 
that have transmission-blocking effect that could be used in 
combination with drugs active against blood-stage parasites. 
E. Improve access to and use of definitive diagnosis-based 
treatment. 
F. Support more widespread use of insecticidetreated materials or 
other appropriate vector control strategies to reduce frequency 
of clinical illness (and therefore, treatment) as well as overall 
malaria transmission.(18)  
 
     Because overall drug pressure is thought to be the single 
most important factor in development of resistance, following more 
restrictive drug use and prescribing practices would be helpful, if not 
essential, for limiting the advent, spread, and intensification of drug 
resistance. This approach has gained support in North America and 
Europe for fighting antibacterial drug resistance.(21, 22)  
 
REFERENCES 
[1] Foster SD. Pricing, distribution, and use of antimalarial drugs. 
Bulletin of the World Health Organization 1991;69:349–363. 
[2] Ridley RG. Plasmodium: Drug discovery and development— an 
industrial perspective. Experimental Parasitology 1997; 87: 
293–304. 
[3] "The History of Malaria, an Ancient Disease". Centers for 
Disease Control. http:// www. cdc. gov/ malaria /history /index. 
htm#chloroquine. 
[4] Plowe CV (2005). "Antimalarial drug resistance in Africa: 
strategies for monitoring and deterrence". Curr. Top. Microbiol. 
Immunol. Current Topics in Microbiology and Immunology 295: 
55–79. doi:10.1007/3-540-29088-5_3. ISBN 3-540-25363-7. 
PMID 16265887.                                                                                               
[5] Uhlemann AC, Krishna S (2005). "Antimalarial multi-drug 
resistance in Asia: mechanisms and assessment". Curr. Top. 
Microbiol. Immunol. Current Topics in Microbiology and 
Immunology 295: 39–53. doi:10.1007/3-540-29088-5_2. 
ISBN 3-540-25363-7. PMID 16265886.                                                                     
[6] Page link: <a href="http://medical dictionary.thefreedictionary.co 
m/Chloroquine-Resistant+Malaria">Chloroquine-Resistant 
Malaria</a>. 
[7] Detecting Drug Resistant Malaria and Tuberculosis in Africa. 
Highlighting achievements of Regional Technical Cooperation 
Project RAF/6/025. International Atomic Energy Agency(IAEA). 
Department of Technical Cooperation, Africa Section. Internet: 
http://www.iaea.org.  
[8] Elbashir MI. The global burden of falciparum malaria and 
strategies for control. In: HE Fadel, MAA Khan, A. a. Mishal, H 
Ur Rahman (eds). Medical Dilemmas in Developing Countries. 
Jordanian Society for Medical studies, Amman, Jordan 2004: 
23-54. 
[9] World Health Organization 2000. WHO Expert Committee on 
Malaria (twentieth report). WHO Technical Report Series No 
892. 
[10] Foly M, Tilly L. Quinoline antimalarials: mechanism of action and 
resistance. International Journal for Parasitology 1997; 27:231-
240.                                                   
[11] Krogstad DJ et al. Efflux of chloroquine from Plasmodium 
falciparum: mechanism of chloroquine resistance. Science 
1987;238:1283–1285.                                      
[12] Martin SK, Oduola AM, Milhous WK. Reversal of chloroquine 
resistance in Plasmodium falciparum by verapamil. Science 
1987;235:899–901. 
[13] Sudan, Country Profile. Available at http://rbm.who .int/wmr2005 
/profiles/sudan.pdf. Accessed April 28, 2005. 
[14] Rieckmann KHL, L Campbell GH, Sax LJ,. Drug sensitivity of 
plasmodium falciparum. An in vitro microtechnique. Lancet 
1978; 1: 22-23. 
[15] World Health Organization, 2001. In vitro Micro-Test (MARK III) 
for the Assessment of the Response of Plasmodium 
falciparum to Chloroquine, Mefloquine, Quinine, Amodiaquine, 
Sulfadoxine/ Pyr-  imethamine  and Artemisinin. 
WHO/MAL/97.20.                               
[16] Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J: 
Assessment of the drug susceptibility of Plasmodium 
falciparum clinical isolates from Africa by using a Plasmodium 
lactate dehydrogenase immunodetection assay and an 
inhibitory maximum effect model for precise measurement of 
the 50-percent inhibitory concentration. Antimicrob Agents 
Chemother 2006, 50:3343-3349.  
[17] Adam I, Elbashir MI. Antimalarial drugs resistance in Sudan. 
Khartoum Medical Journal 2008; 1 (1) : 7-11.                                   
18-Bloland PB, Drug resistance in malaria. World Health 
Organization WHO/CDS/CSR/DRS /2001;4 : 1 – 23.                           
[18] White NJ et al. Averting a malaria disaster. Lancet 
1999;353:1965–1967. 
[19] Wernsdorfer WH, Chongsuphajaisiddhi T, Salazar NP. A 
symposium on containment of mefloquineresistant falciparum 
malaria in Southeast Asia with special reference to border 
malaria. Southeast Asian Journal of Tropical Medicine & Public 
Health 1994;25:11–18. 
Akasha and Badah  
 
26
[20] Seppälä H et al. The effect of changes in the consumption of 
macrolide antibiotics on erythromycin resistance in Group A 
streptococci in Finland. New England Journal of Medicine 
1997;337:441– 446. 
[21] Bauchner H, Pelton SI, Klein JO. Parents, physicians, and 
antibiotic use. Pediatrics 1999;103:395– 401.
 
 
 
 
 
